top of page

4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board

LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Kenya Honda to its Scientific Advisory Board (SAB).

Professor Honda is a Professor in the Department of Microbiology and Immunology at Keio University School of Medicine, Tokyo, Japan. Professor Honda’s team is studying the immunological attributes of the microbiota and its derived factors to try to identify responsible members that deeply affect the immune system. His long-term goal is to develop a way to manipulate and normalize compositions of the gut microbiota to treat various conditions, such as inflammatory bowel disease (IBD), autoimmunity, allergies and cancer.

Professor Honda brings significant expertise to 4BIO’s SAB. He is the Scientific Co-Founder of Vedanta Biosciences, a Cambridge, MA-based company pioneering the use of defined bacterial consortia, as well as being a member of the SAB for the interdisciplinary medical journal, Science Translational Medicine. Professor Honda received his M.D. from Kobe University School of Medicine and his Ph.D. from Kyoto University School of Medicine, both in Japan. His contribution to scientific research has been internationally recognised, having been awarded the National Institute of Science and Technology Policy (NISTEP) Award in 2013, the Gottfried Wagener Prize in 2014, and the Bäelz award in 2016.

Dmitry Kuzmin, Managing Partner at 4BIO Capital, said: “4BIO’s Scientific Advisory Board includes founders of the gene therapy field in both academic and hospital settings who lead groups in world centres of academic and clinical excellence. Professor Honda’s extensive knowledge of microbiota and gastrointestinal tract pathology will be a valuable addition to the already deep expertise held within the 4BIO SAB. Professor Honda’s appointment builds on the recent appointment of Philippe Fauchet, OBE, as Venture Partner in Japan, and the strategic investment in 4BIO from Japanese Pharmaceutical company Kyowa Kirin. As one of the leading countries in drug discovery and advanced gene and cell therapy research, we are excited by the potential opportunities of our expanded footprint in Japan.”

Professor Kenya Honda said: “I am delighted to be joining the 4BIO team and working with the other advisors that have helped shape the advanced therapies field and contributed to its progress. I look forward to working closely with this group in the pursuit of opportunities in advanced therapies, particularly the exciting research originating from Japan at this time.”


先端医療に特化する国際的なベンチャーキャピタルの4BIOキャピタル(4BIO Capital、本社ロンドン)は、本田賢也教授を同社の科学顧問委員会(Scientific Advisory Board)に迎えたことをお知らせします。


本田教授は重要な専門知識を4BIOの科学顧問委員会にもたらします。同氏は、定義された細菌共生体を活用する先駆的な研究を打ち出す米VEDANTA BIOSCIENCES(本社マサチューセッツ州ケンブリッジ市)の科学における共同創立者であると同時に、学際的な医学ジャーナルScience Translational Medicineの科学顧問委員会の委員も務めています。教授は神戸大学医学部で医学博士号を、京都大学大学院医学研究科・医学部で博士号を取得しました。医学への貢献は国際的に評価され、2013年には科学技術・学術政策研究所(NISTEP)賞、2014年にはゴットフリード・ワグネル賞、そして2016年にはベルツ賞を受賞しています。



bottom of page